Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

BioLineRx (BLRX) Net Income towards Common Stockholders: 2023-2025

Historic Net Income towards Common Stockholders for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to -$2.0 million.

  • BioLineRx's Net Income towards Common Stockholders rose 45.04% to -$2.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$7.7 million, marking a year-over-year increase of 80.04%. This contributed to the annual value of -$11.3 million for FY2024, which is 76.25% up from last year.
  • As of Q2 2025, BioLineRx's Net Income towards Common Stockholders stood at -$2.0 million, which was down 2.84% from -$2.0 million recorded in Q1 2025.
  • Over the past 5 years, BioLineRx's Net Income towards Common Stockholders peaked at $54,000 during Q4 2024, and registered a low of -$19.5 million during Q4 2023.
  • In the last 3 years, BioLineRx's Net Income towards Common Stockholders had a median value of -$3.8 million in 2024 and averaged -$6.3 million.
  • Data for BioLineRx's Net Income towards Common Stockholders shows a peak YoY soared of 100.28% (in 2024) over the last 5 years.
  • BioLineRx's Net Income towards Common Stockholders (Quarterly) stood at -$19.5 million in 2023, then soared by 100.28% to $54,000 in 2024, then skyrocketed by 45.04% to -$2.0 million in 2025.
  • Its Net Income towards Common Stockholders was -$2.0 million in Q2 2025, compared to -$2.0 million in Q1 2025 and $54,000 in Q4 2024.